Jardiance

Chemical Nameempagliflozin
Dosage FormTablets (oral; 10mg, 25mg)
Drug ClassInhibitors
SystemEndocrine, Cardiovascular
CompanyBoehringer Ingelheim Pharmaceuticals
Approval Year2014

Indication

  • An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
  • To reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.
Last updated on 4/20/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Jardiance (empagliflozin) Prescribing Information2014Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT
Document TitleYearSource
Effects and safety of SGLT2 inhibitors compared to placebo in patients with heart failure: A systematic review and meta-analysis.2021IJC Heart and Vasculature
Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: A systematic review and network meta-analysis. 2020Annals of Internal Medicine
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. 2020The Lancet Diabetes and Endocrinology
Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map. 2020The Lancet Diabetes and Endocrinology
Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis.2020PLoS One
Efficacy and safety of SGLT-2 inhibitors for treatment of diabetes mellitus among kidney transplant patients: A systematic review and meta-analysis.2020Medical Sciences
Effect of sodium-dependent glucose transporter inhibitors on glycated hemoglobin A1c after 24 weeks in patients with diabetes mellitus: A systematic review and meta-analysis.2020Medicine
Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis.2019PLoS Medicine
Peripheral artery disease and amputations with Sodium-Glucose co-Transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials. 2019Diabetes Research and Clinical Practice
Cardiovascular safety of empagliflozin versus dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetes: Systematic literature review and indirect comparisons.2018Diabetes Therapy
Efficacy and safety of empagliflozin for type 2 diabetes mellitus: Meta-analysis of randomized controlled trials.2018Medicine
SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and meta-analysis. 2018Diabetes Obesity and Metabolism
Effects of sodium glucose cotransporter-2 inhibitors on serum uric acid in type 2 diabetes mellitus: A systematic review with an indirect comparison meta-analysis.2018Saudi Journal of Biological Sciences
Dose response of sodium glucose cotransporter-2 inhibitors in relation to urinary tract infections: a systematic review and network meta-analysis of randomized controlled trials.2018CMAJ Open
Risks of diabetic foot syndrome and amputation associated with sodium glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials. 2018Diabetes and Metabolism
SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials.2017Diabetologia
Systematic review of metformin monotherapy and dual therapy with sodium glucose co-transporter 2 inhibitor (SGLT-2) in treatment of type 2 diabetes mellitus. 2017Diabetes Research and Clinical Practice
Sodium–glucose cotransporter 2 inhibitors and risk of adverse renal outcomes among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials.2017Diabetes Obesity and Metabolism
Meta-analysis of effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular outcomes and all-cause mortality among patients with type 2 diabetes mellitus.2016The American Journal of Cardiology
Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: A systematic review and meta-analysis.2016PLoS One
Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials.2016Diabetes Obesity and Metabolism